Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

390 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.
Parisi A, Cortellini A, Cannita K, Venditti O, Camarda F, Calegari MA, Salvatore L, Tortora G, Rossini D, Germani MM, Boccaccino A, Dell'Aquila E, Fulgenzi C, Santini D, Tursi M, Tinari N, Marino PD, Lombardi P, Keränen SR, Álvaro MH, Zurlo IV, Corsi DC, Emiliani A, Zanaletti N, Troiani T, Vitale P, Giampieri R, Merloni F, Occhipinti MA, Marchetti P, Roberto M, Mazzuca F, Ghidini M, Indini A, Garajova I, Zoratto F, Monache SD, Porzio G, Ficorella C. Parisi A, et al. Among authors: lombardi p. Cancers (Basel). 2020 May 16;12(5):1259. doi: 10.3390/cancers12051259. Cancers (Basel). 2020. PMID: 32429380 Free PMC article.
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
Parisi A, Porzio G, Cannita K, Venditti O, Avallone A, Filippi R, Salvatore L, Tortora G, Ribelli M, Nigro O, Gelsomino F, Spallanzani A, Zurlo V, Leo S, Dell'Aquila E, Claudia F, Lombardi P, Keränen SR, Aimar G, Depetris I, Giampieri R, Morelli C, De Tursi M, Tinari N, Di Pietro FR, De Galitiis F, Zanaletti N, Troiani T, Vitale P, Garajova I, Ghidini M, Spinelli GP, Zoratto F, Roberto M, Ierino D, Petrillo A, D'Orazio C, Ficorella C, Cortellini A. Parisi A, et al. Among authors: lombardi p. Clin Colorectal Cancer. 2021 Dec;20(4):318-325. doi: 10.1016/j.clcc.2021.07.003. Epub 2021 Jul 18. Clin Colorectal Cancer. 2021. PMID: 34380594
Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials.
Duranti S, Fabi A, Filetti M, Falcone R, Lombardi P, Daniele G, Franceschini G, Carbognin L, Palazzo A, Garganese G, Paris I, Scambia G, Pietragalla A. Duranti S, et al. Among authors: lombardi p. Cancers (Basel). 2021 Oct 16;13(20):5198. doi: 10.3390/cancers13205198. Cancers (Basel). 2021. PMID: 34680350 Free PMC article. Review.
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study.
Parisi A, Cortellini A, Venditti O, Filippi R, Salvatore L, Tortora G, Ghidini M, Nigro O, Gelsomino F, Zurlo IV, Fulgenzi C, Lombardi P, Roselló Keränen S, Depetris I, Giampieri R, Morelli C, Di Marino P, Di Pietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli GP, Zoratto F, Roberto M, Petrillo A, Aimar G, Patruno L, D'Orazio C, Ficorella C, Ferri C, Porzio G. Parisi A, et al. Among authors: lombardi p. Front Oncol. 2021 Oct 27;11:712053. doi: 10.3389/fonc.2021.712053. eCollection 2021. Front Oncol. 2021. PMID: 34778029 Free PMC article.
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
Lombardi P, Rossini D, Crespi V, Germani MM, Bergamo F, Pietrantonio F, Santini D, Allegrini G, Daniel F, Pagani F, Antoniotti C, Zaniboni A, Conca V, Latiano TP, Boccaccino A, Passardi A, Tamburini E, Masi G, Di Maio M, Cremolini C. Lombardi P, et al. Cancer Treat Rev. 2022 Feb;103:102326. doi: 10.1016/j.ctrv.2021.102326. Epub 2021 Dec 23. Cancer Treat Rev. 2022. PMID: 35016085
Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years.
Falcone R, Lombardi P, Filetti M, Duranti S, Pietragalla A, Fabi A, Lorusso D, Altamura V, Paroni Sterbini F, Scambia G, Daniele G. Falcone R, et al. Among authors: lombardi p. Cancers (Basel). 2022 Feb 11;14(4):889. doi: 10.3390/cancers14040889. Cancers (Basel). 2022. PMID: 35205637 Free PMC article.
Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers.
Falcone R, Filetti M, Lombardi P, Altamura V, Paroni Sterbini F, Scambia G, Daniele G. Falcone R, et al. Among authors: lombardi p. Explor Target Antitumor Ther. 2023;4(4):716-726. doi: 10.37349/etat.2023.00163. Epub 2023 Aug 31. Explor Target Antitumor Ther. 2023. PMID: 37711591 Free PMC article.
Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis.
Filetti M, Lombardi P, Falcone R, Giusti R, Giannarelli D, Carcagnì A, Altamura V, Scambia G, Daniele G. Filetti M, et al. Among authors: lombardi p. Explor Target Antitumor Ther. 2023;4(6):1136-1144. doi: 10.37349/etat.2023.00187. Epub 2023 Dec 1. Explor Target Antitumor Ther. 2023. PMID: 38213541 Free PMC article.
390 results